Co-design and implementation research: challenges and solutions for ethics committees by unknown
DEBATE Open Access
Co-design and implementation research:
challenges and solutions for ethics
committees
Felicity Goodyear-Smith1* , Claire Jackson2 and Trisha Greenhalgh3
Abstract
Background: Implementation science research, especially when using participatory and co-design approaches,
raises unique challenges for research ethics committees. Such challenges may be poorly addressed by approval and
governance mechanisms that were developed for more traditional research approaches such as randomised
controlled trials.
Discussion: Implementation science commonly involves the partnership of researchers and stakeholders,
attempting to understand and encourage uptake of completed or piloted research. A co-creation approach
involves collaboration between researchers and end users from the onset, in question framing, research design and
delivery, and influencing strategy, with implementation and broader dissemination strategies part of its design from
gestation. A defining feature of co-creation is its emergent and adaptive nature, making detailed pre-specification
of interventions and outcome measures impossible. This methodology sits oddly with ethics committee protocols
that require precise pre-definition of interventions, mode of delivery, outcome measurements, and the role of study
participants. But the strict (and, some would say, inflexible) requirements of ethics committees were developed for
a purpose – to protect participants from harm and help ensure the rigour and transparency of studies. We propose
some guiding principles to help square this circle. First, ethics committees should acknowledge and celebrate the
diversity of research approaches, both formally (through training) and informally (by promoting debate and
discussion); without active support, their members may not understand or value participatory designs. Second,
ground rules should be established for co-design applications (e.g. how to judge when ‘consultation’ or
‘engagement’ becomes research) and communicated to committee members and stakeholders. Third, the benefits
of power-sharing should be recognised and credit given to measures likely to support this important goal,
especially in research with vulnerable communities. Co-design is considered best practice, for example, in research
involving indigenous peoples in New Zealand, Australia and Canada.
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Background
Findings from clinical trials, even when disseminated
widely in journals and conference presentations and in-
corporated into clinical practice guidelines, do not al-
ways change clinical practice or produce patient-relevant
impacts [1]. One reason for this is that interventions
which fit closely to context in one setting (e.g. are
acceptable, operationally feasible, affordable and cultur-
ally congruent) may be a poor fit in another setting.
The question of ‘fit’ is the basis for the emerging dis-
cipline of implementation science – research that ad-
dresses the application of interventions in ‘real world’
settings with a view to understanding what works, how
and why, in specific contexts, and testing approaches to
improve their implementation and effective uptake [2].
Here, the focus is on knowledge production and transla-
tion (rather than dissemination of findings), exploring
such issues as factors influencing implementation, the
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results of implementation, and how to scale up an inter-
vention to achieve wider uptake and sustainability.
In conventional clinical trials, different contexts are
generally controlled or adjusted for, and populations made
as homogenous as possible, with atypical settings and out-
liers excluded. Protocols are prescriptive and standardised,
with the aim to reduce ‘noise’ and create the circum-
stances for ideal implementation. In contrast, implementa-
tion research embraces heterogeneity, addressing complex
system integration, and developing an adaptive framework
to enable context-sensitive scale-up that is equitable for
different populations [3]. Successful implementation in-
volves ongoing adaption to a changing context and feed-
back processes for longer term spin-offs, transposition
and sustainability. Rather than logic models (linking
inputs to processes and outputs in a more or less linear
way) and point estimates of effect, implementation re-
search uses theory of change, examining natural diversity
and the interaction of the intervention in context to
produce actionable knowledge. It often uses mixed (quan-
titative and qualitative) methodologies, and analyses in
terms of ‘intention to reach’, rather than ‘intention to treat’,
for equitable population health impact [4].
One approach to implementation research involves de-
veloping democratic partnerships between researchers
and community stakeholders with a view to involving
end-users in the design of research, promoting their
understanding and capacity, and encouraging uptake of
findings [5]. This may involve iterative processes of re-
flection and action, ‘carried out with and by local people
rather than on them’ [6]. Known as participatory action
research, this methodology seeks to empower partici-
pants to tailor an intervention to suit their own contexts.
Interventions need to have contextual fit, to be respon-
sive to the community and the participants they serve
[5]. Stakeholders may be the potential recipients of the
intervention, or responsible for implementing it, including
patients, health care providers, managers and policy-
makers. Ideally, collaboration occurs between researchers
and end users from the onset – in question framing,
research design and delivery, and influencing strategy.
This co-creation approach places end-user value at its
very heart, with implementation and broader dissemin-
ation strategies part of its design from gestation. It also
generally seeks to establish an ongoing, collaborative
approach between researchers and end users, which is
long-term rather than programme or project-specific; and
which builds synergistically as partners build trust, work
together and learn from successive projects [5, 7].
Ramaswamy et al., in their ‘Cocreation Paradigm’, de-
scribe six steps toward a culture of operational co-creation:
1. Identify the key stakeholders and promote their
willingness to engage
2. Set up platforms purposefully designed to engage
more co-creatively
3. Identify and support new champions
4. Expand the circle of stakeholders and joint value
creation opportunities
5. Deepen the impact and enable the spread of more
win-more, win-more strategies
6. Engage stakeholders to expand benefits for all [8].
Examples of the success of this approach in ‘locking
down’ research uptake into the dynamic and time-
constrained environment of community-based healthcare
are accumulating [9–13]. However, because collaborative
partnerships inevitably bring logistical complexities as well
as competing values and conflicts of interest, challenges to
research governance, flexibility and timeframes are com-
mon [9, 10, 14–16].
One particular challenge in co-creation research, and
the focus of the remainder of this paper, relates to the
traditional ethics approval processes.
Discussion
Challenges in gaining ethics committee approval in
co-creation research
Research involving human participants puts people at
risk, largely for the benefit of the researchers [17]. The
current system of research ethics in biomedicine emerged
partly as a response to international scandals such as the
infamous experiments on prisoners under the Nazi regime
and the Tuskeegee syphilis study (in which life-saving treat-
ment was withheld from poor Black Americans, who had
no knowledge of the research, for more than 30 years) [18].
Building on the landmark Nuremberg Code [19] the Dec-
laration of Helsinki [20] and the International Ethical
Guidelines for Biomedical Research Involving Human
Subjects, [21] medical research has become increasingly
regulated in the past five decades. Formal codes of practice
are now the norm, with the goal of ensuring that the meth-
odology is rigorous; that potential harm to participants is
minimised; that people know exactly what they are signing
up to; and that the potential benefits of study outcomes
outweigh possible risks of safety or confidentiality.
To that end, current clinical ethics and governance
procedures are oriented to confirming that research inter-
ventions (drugs, procedures, educational or behavioural
measures) are carefully defined and explained to potential
participants before they agree to join the study; that con-
sent procedures are non-coercive; that people receive
no more or less than the intervention(s) stipulated in
the protocol; that responses to that intervention are
systematically monitored; that the welfare and choices
of participants remain paramount (even if this necessi-
tates withdrawing people from a study or compromis-
ing on what data are collected); and that a clear trail of
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accountability can be demonstrated should harm occur.
Such procedures have been criticised for being bureau-
cratic, inefficient and inconsistent, [22] but there is broad
agreement that a stringent and transparent system of
governance is preferable to a repeat of past scandals [23].
By their nature, intervention studies (offering a drug,
procedure or complex intervention with the aim of pre-
venting, diagnosing or managing a condition and then
assessing its effectiveness and safety) carry greater risk
to participants than observational studies (in which no
active manoeuvre is offered beyond usual care). Ethics
committees rightly view themselves as responsible for
what interventions are offered, to whom, and how. Fur-
thermore, as much clinical research has become centred
on randomised controlled trials (many of which are spon-
sored by industry), research governance has evolved to
ensure that clinical trials are registered at the outset to
prevent selective censorship of negative results [24] and to
reduce protocol deviations (e.g. alteration of drug dose or
scheduling, change of primary endpoint or length of
follow-up) designed to influence the outcome [25].
Increasingly, therefore, the role of research ethics com-
mittees (institutional review boards in USA) is to carefully
check study protocols and supporting documentation in
advance of an intervention study and then ensure that
these are strictly adhered to for its duration. For complex
interventions, pre-specified information is likely to include
participants’ anticipated time commitment, interview
schedules, questionnaires and so on. This rational and
(some would say) technocratic approach means that flexi-
bility, adaptation to context and the very essence of co-
creation is systematically ‘designed out’.
Pre-specification of the study protocol and other docu-
ments is a quality feature in randomised trials. But when
the focus of research is the achievement of intervention-
system fit (as in implementation science) and/or the emer-
gent co-creation of research through multi-stakeholder
partnerships, rigid pre-specification is at best ironic and at
worst a recipe for failure, since by definition, the definitive
intervention and its application is not pre-determined. Ra-
ther, the research question, the nature and delivery of the
intervention and how its impact is measured, must be co-
determined by researchers and other stakeholders – usu-
ally over weeks or months and in parallel with establishing
programme governance, developing research capacity in
community partners, building trust and working through
conflict. These are ongoing and mutually reinforcing pro-
cesses, not one-off procedures that can be ticked off as
having been ‘achieved’.
Because of the emergent nature of the co-creation
process and the crucial importance of relationships and
partnership synergy, compromises may need to be made
with respect to methodology to facilitate impact. But this
emergent methodology creates unique challenges to ethics
committees, whose protocols, as noted above, tend to
require precise definition of the intervention, its mode of
delivery, outcome measurements, and the role of partici-
pants in the study.
Some principles for handling ethics committee
applications in implementation research involving
co-creation elements
The need (on the one hand) to co-create and adapt in-
terventions for the purposes of maximising fit and (on
the other hand) to pre-specify them for the purposes of
ethical approval creates a tension for which there is no
simple or formulaic solution. Furthermore, it is import-
ant, whilst acknowledging the need for flexibility in some
studies, not to create loopholes that will allow partisan
interests to ‘move the goalposts’ in more conventional
research designs.
Furthermore, ethics committees aim to protect the au-
tonomy and rights of individuals participating in clinical
research, but individually-based ethical frameworks are
not necessarily of benefit to the community at large,
who are collectively involved in the research process [26].
With co-creation design, there is a move from protection
of individual participants to the development of a relation-
ship between researchers and community partners which
is mutually advantageous [27]. The participant is not
someone on whom research is ‘done’, but is actively en-
gaged in designing and implementing the research process.
Banks et al., writing about community-based participa-
tory research (CBPR, a type of co-creation research linked
to community development and the quest for social
justice), point out that whereas conventional research
ethics is principle-based and focused primarily on ensur-
ing rule-following to meet regulatory requirements, CBPR
is value-based and focused on relationships and the distri-
bution of power between ‘researchers’ and ‘researched’
(and acknowledging that the boundaries between these
groups may be blurred) [28].
With these caveats in mind, and assuming that co-
creation approaches will continue to be assessed by
existing systems of research governance, we offer four
principles to guide ethics committees when considering
applications.
First, ethics committees should acknowledge and cele-
brate the diversity of research – both formally (by ensur-
ing that ethics committee members receive broad training
in the full range of research methods, study designs and
the rationale for these) and informally (by encouraging
discussion and debate). The make-up of research ethics
committees may be very diverse, with individual members
who may be selected for their professional expertise in
different fields (for example nursing, law, ethics) and/or
for their ‘lay’ contribution – but these members may have
little or no formal training in research methodologies [29].
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Even those well versed in laboratory science or rando-
mised trials may have little knowledge or understanding
of the characteristics of high-quality implementation and/
or co-design research. Researchers can play their part in
educating committee members on the nature of such
research, and why a co-creation approach may increase
the likelihood of impact and reduce harm to participants.
Other commentators have similarly highlighted the im-
portance of educating ethics committees in this regard
[30]. Approaches may include researchers explicitly men-
tioning these issues in their application; supplying a key
paper outlining this type of research as supplementary ma-
terial; or seeking the opportunity to meet with the commit-
tee and explain co-design in the context of their proposal.
Second, researchers and other stakeholders in the co-
creation process should work with research ethics com-
mittees, perhaps at national level, to establish some
ground rules for participatory research applications and
communicate these to all parties. For example, prelimin-
ary consultation with potential beneficiaries (‘patients
and carers’) is already defined by most ethics committees
as a necessary step before an application can be submit-
ted. While a Code of Research Ethics has previously
been developed for participatory research, [31] this was
not intended to be imposed on all research; rather to be
individually developed for different projects [32]. Estab-
lishing partnership governance and outlining the core
components of a planned intervention can and should
begin before the ethics application is finalised. There are
likely to be some components that are integral aspects
of the intervention, not amenable to change, and other
aspects such as the setting or application that can be co-
created. Hawe et al’s distinction between the theoretical
‘core’ of a complex intervention, which must be kept
constant, and its local application, which can and should
be flexible across sites and settings, may be a useful con-
ceptual framework [33]. It will often (though perhaps
not always) be possible to make explicit the elements
open to modification, and stipulate the nature of the
facilitation process through which this will occur.
Third, research ethics committees should acknowledge
the benefits of power-sharing in the co-design process
and give credit to measures that support this goal; re-
searchers in turn should make such measures explicit in
their ethics applications. The reciprocity of co-creation
serves to diminish participant risk. Researchers and stake-
holders work together, and this power-sharing – to the
extent that it is effective – will serve to reduce inequality
and empower vulnerable communities. Co-design, for
example, is considered best practice in research involving
indigenous peoples (some of whom are especially vulner-
able and/or have been exploited by researchers in the past
[34]). In New Zealand, best practice is methodology that
empowers indigenous Māori to take a governance role in
the ‘planning, development and execution of research as
well as monitoring the project through its life cycle’ [35].
In Australia, it is recognised that ‘indigenous communities
and individuals have a right to be involved in any research
project focused upon them and their culture’ and re-
searchers are encouraged to include Traditional Owners,
custodians, Elders, and community members to be in-
volved in the research as collaborators, advisers or assis-
tants [36]. Similarly the Canadian Panel of Ethics directs
that research involving Aboriginal peoples in Canada, in-
cluding Indian (First Nations), Inuit and Métis peoples,
should be premised on respectful relationships, and
encourages collaboration and engagement between re-
searchers and participants [37].
Finally, our fourth principle is one of emergence and
continuing learning by all parties. The ethics of co-creation
are an emerging area on which there is, appropriately,
ongoing debate. Other commentators in the recent litera-
ture have made suggestions about how ethics committees
may consider participatory research. Chen and colleagues,
for example, suggest a framework which includes respect
for potential and enrolled participants, community part-
ners and research partners [38]. Another study failed to
find consensus regarding who represents and speaks for a
community [26]. Blake proposes participants only signing
consent forms after all interviews or focus groups have
been completed, and including preferences regarding ano-
nymity and use of audio recordings [39].
To continue to inform the debate, we suggest that data
should be prospectively collected on the types of appli-
cations that are received by research ethics committees
how issues such as the lack of a definitive intervention
and its application have been addressed, and identifica-
tion of the learning points, and these findings dissemi-
nated. Examination of such cases and how they have
been resolved will help to move the debate onwards.
Collecting and assessing such data could be a role for
organisations such as the National Research Ethics
Service (now part of the Health Research Authority) in
the UK, and the Health and Disability Ethics Committee
in New Zealand, which are charged with ensuring that
the rights and safety of research participants are pro-
tected, and ethical research of potential benefit to sci-
ence and society is conducted.
Conclusions
There is no simple answer to the question of how to bal-
ance the laudable principle of co-creation with the need
for robust and transparent governance of research on
human participants. The principles proposed in this
paper are preliminary; we invite discussion and recom-
mend further research on the ethical dimension of this
rapidly developing field.
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